Skin Conditions & Dermatology Clinical Trials Update: Week 24, 2026

Published June 12, 2026 — 5 trials covered

By Victor Lafforgue, Founder of TrialsAlert. Blog posts are AI-drafted from ClinicalTrials.gov source data and reviewed by the editorial team. See our editorial policy for details.

A Study to Evaluate the Drug Levels, Efficacy and Safety of Deucravacitinib in Children and Adolescent Participants With Moderate to Severe Plaque Psoriasis

This Phase 3 trial is testing deucravacitinib, an oral medication, in children and adolescents aged 4 to under 18 years with moderate to severe plaque psoriasis. If successful, it could provide a new treatment option that is easier to take and may have fewer side effects compared to current therapies. The study is recruiting participants worldwide, offering hope for younger patients who need effective and manageable care.

A Study To Assess Adverse Events and Effectiveness of Upadacitinib Oral Tablets in Adult and Adolescent Participants With Vitiligo

This ongoing Phase 3 trial is evaluating the safety and effectiveness of upadacitinib tablets for adults and adolescents living with non-segmental vitiligo, a condition that causes loss of skin color. The potential new treatment aims to improve skin pigmentation and reduce the disease’s impact. Although the study is not recruiting, results are expected after long-term follow-up across multiple countries, which may offer new options for people affected by vitiligo.

Cardamom and Topical Roseomonas in Atopic Dermatitis

This Phase 2 study is exploring a novel topical treatment combining Roseomonas mucosa bacteria and ground cardamom seeds for individuals aged 2 years and older with atopic dermatitis, also known as eczema. This approach could provide an easy-to-use alternative that improves symptoms without relying on traditional medications. The trial is recruiting in the United States and includes remote visits, making participation more accessible for families.

Maximizing Laser Therapy Success for Port-Wine Birthmarks in Pediatric Patients

This study focuses on improving laser treatment for children with Port-Wine Birthmarks, aiming to reduce the number of sessions and avoid the need for general anesthesia. By making treatment safer and less stressful, this research could improve the experience and outcomes for young patients. The trial is recruiting in the United States and plans to include 200 pediatric participants.

A Real-world Study of Deucravacitinib in the Treatment of Moderate to Severe Plaque Psoriasis With Eczematous Features

This research is examining deucravacitinib for adults with moderate to severe plaque psoriasis that also shows eczematous features. Conducted in China, the study aims to see if this oral medication can effectively treat both psoriasis and eczema symptoms with fewer side effects. Patients enrolled will be monitored over 16 weeks to assess the treatment’s impact.

This week in skin conditions and dermatology research shows promising advances in treatments for children and adults alike. Studies are exploring easier, potentially safer options for psoriasis, vitiligo, eczema, and birthmarks. These efforts reflect ongoing progress toward improving quality of life for those affected by skin conditions.

TrialsAlert subscribers received the full impact-classified briefing and doctor-ready report this week. Get weekly briefings at trialsalert.com.